Status:
RECRUITING
Ocular Complications From Cancer Therapy - Patient Registry and Biobank
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Graft Versus Host Disease in Eye
Ocular Complications
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to collect data on patients seen at University of Maryland after undergoing cancer therapy. Previous medications, ocular history, medical history, clinical evaluations, su...
Detailed Description
The objective of this study is to evaluate and study the immunologic changes in patients who undergo cancer therapy, specifically identifying patients who are at risk of developing ocular complication...
Eligibility Criteria
Inclusion
- Inclusion Criteria for the Cancer Therapy Group:
- Adult patients (greater than 18 years of age)
- Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery)
- Patients who have a history of allogenic HSCT with all stem cell sources including bone marrow, PBSC, cord AND/OR patients with a history of prior cancer therapy including BMT, chemotherapy, and immunotherapy
- Patients will be recruited after their HSCT or cancer therapy at their ophthalmology appointment
- Patients can be included with a history of prior cancer therapy including chemotherapy, BMT, immunotherapy. Prior cancer therapy must be identified and documented.
- The patient must be able to understand and sign and date the informed consent form approved by the IRB.
- Inclusion Criteria for the Control Group:
- No history of cancer or cancer therapy in the past
- Adult patients (greater than 18 years of age)
- Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery)
- The patient must be able to understand and sign and date the informed consent form approved by the IRB.
- Exclusion Criteria for the Cancer Therapy Group:
- Vulnerable populations: neonates, children, prisoners, institutionalized individuals
- Inability or refusal to provide informed consent.
- History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma).
- Exclusion Criteria for the Control Group:
- Vulnerable populations: neonates, children, prisoners, institutionalized individuals
- Inability or refusal to provide informed consent.
- History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma).
- History of cancer or cancer therapy including chemotherapy, immunotherapy, BMT.
Exclusion
Key Trial Info
Start Date :
May 13 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2031
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06874283
Start Date
May 13 2025
End Date
April 1 2031
Last Update
July 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stoler Outpatient Cancer Center at the University of Maryland
Baltimore, Maryland, United States, 21201